Jose Cardona

发表

Randomized placebo-controlled trials of remdesivir in severe COVID-19 patients: A Systematic Review and Meta-analysis

M. Sanchez-Gonzalez, Z. Sarfraz, A. Sarfraz, 2020, medRxiv.

Randomized controlled trials of remdesivir in hospitalized coronavirus disease 2019 patients: A meta-analysis

E. Angueira, J. Posada, M. Sanchez-Gonzalez, 2021, Turkish journal of emergency medicine.

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

D. Skovronsky, Lei-Bin Shen, V. Stosor, 2020, The New England journal of medicine.

A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load

D. Skovronsky, R. Higgs, T. Holzer, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.

N. Gallagher, R. Mularski, Julie M. Skinner, 2022, The Lancet. Infectious diseases.

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

D. Skovronsky, R. Higgs, T. Holzer, 2021, The New England journal of medicine.

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

D. Skovronsky, R. Higgs, T. Holzer, 2021, JAMA.

A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).

R. Dagan, M. Haranaka, A. Pedley, 2021, Vaccine.

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years

Stephen J. Thomas, N. Kitchin, S. Lockhart, 2023, The New England journal of medicine.

Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.

W. Gruber, D. Scott, Dung-Yang Lee, 2023, Vaccine.

P09 A Phase 2, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine (V116) in adults ≥50 years

R. Mularski, Neil J. Fraser, A. Sapre, 2023, JAC-Antimicrobial Resistance.

Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.

E. Walsh, A. Falsey, F. Polack, 2023, The New England journal of medicine.

Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial

M. Nangaku, D. de Zeeuw, F. Schulze, 2023, Diabetes, obesity & metabolism.

D. Skovronsky, R. Higgs, T. Holzer, 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study

S. Silverman, B. Mitlak, N. Binkley, 2023, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.